Hungary: Pricing and reimbursement reforms aiming to remove hurdles to late market access of innovative pharmaceuticals

In brief

Reimbursing medicinal products is critical to ensure that treatments are widely available to patients. This is especially true for innovative products and is expected to become even more important with the EU Pharma reform package.

Pricing and reimbursement (P&R) is an area regulated at Member State level, and on average the regulatory approach in Hungary has been on the stricter side for new medicinal products causing delay to market access. However recent legal reforms in Hungary on P&R aim to improve the situation and ensure earlier access for patients to innovative medicines. Whether these improvements will be reflected in legal practice remains to be seen.


In more detail

In Hungary, obtaining a P&R approval currently requires that the medicinal product is already marketed with reimbursement in at least three other EEA countries because the product may not have a reimbursed price in Hungary that is higher than the mathematical average of the same product's price in at least three EEA countries (actually the lowest priced countries if the product is reimbursed in more than three countries). This rule prevents Hungary from being an early adopter for pharmaceuticals. Due to a recent amendment, this restriction will no longer apply with effect from 1 June 2023. Thus, if the medicinal product is reimbursed in less than three EEA countries, then the average of the reimbursed price in the given two EEA countries, or the single EEA country will apply. If the product is not reimbursed in any EEA countries, this will no longer prevent inclusion into reimbursement either. The new rule is primarily aimed at facilitating market access of Hungarian innovative manufacturers, but lifting the restriction can also benefit foreign MAHs.

This is also a positive development in light of the EU Pharma Reform Package Proposal that was issued by the Commission on 26 April. The EU proposal would expect marketing authorization holders (MAH) to ensure patient access in EU countries within two (or in exceptional cases, three) years of obtaining a marketing authorization (MA) to keep the same data exclusivity period that is currently applicable (i.e., eight years).

The above amendment follows an earlier development in February 2023, which changed the assessment procedure for named-patient reimbursement (NPR) requests. This procedure became more stringent in an effort to reduce overspending within the NPR budget and to encourage MAHs to file regular reimbursement requests instead of using the NPR route. Further to this change, if an application for NPR is received for a medicinal product that has not yet been assessed by the counseling committee of the Ministry of Health (MoH), the application will also be examined by the Professional Counseling Committee and the Social-ethics Decisional Committee operating alongside the Health Insurance Fund Administration (NEAK). This is a significant change given that previously the NEAK only had to consult a single competent doctor when evaluating NPR applications. Although the NEAK will not be bound by the opinions of the two advisory committees, the procedure will likely become more objective and formal. According to a press statement of NEAK, the NEAK intends to accelerate the normal reimbursement process and achieve that the MoH will also cooperate in streamlining the currently lengthy process of legislative amendments to get closer to the statutory 90 day-limit. It remains to be seen if the NEAK and MoH can achieve their stated goals.

Contact Information
Helga Biro
Partner at BakerMcKenzie
Read my Bio
Mate Laczko
Associate at BakerMcKenzie

Copyright © 2024 Baker & McKenzie. All rights reserved. Ownership: This documentation and content (Content) is a proprietary resource owned exclusively by Baker McKenzie (meaning Baker & McKenzie International and its member firms). The Content is protected under international copyright conventions. Use of this Content does not of itself create a contractual relationship, nor any attorney/client relationship, between Baker McKenzie and any person. Non-reliance and exclusion: All Content is for informational purposes only and may not reflect the most current legal and regulatory developments. All summaries of the laws, regulations and practice are subject to change. The Content is not offered as legal or professional advice for any specific matter. It is not intended to be a substitute for reference to (and compliance with) the detailed provisions of applicable laws, rules, regulations or forms. Legal advice should always be sought before taking any action or refraining from taking any action based on any Content. Baker McKenzie and the editors and the contributing authors do not guarantee the accuracy of the Content and expressly disclaim any and all liability to any person in respect of the consequences of anything done or permitted to be done or omitted to be done wholly or partly in reliance upon the whole or any part of the Content. The Content may contain links to external websites and external websites may link to the Content. Baker McKenzie is not responsible for the content or operation of any such external sites and disclaims all liability, howsoever occurring, in respect of the content or operation of any such external websites. Attorney Advertising: This Content may qualify as “Attorney Advertising” requiring notice in some jurisdictions. To the extent that this Content may qualify as Attorney Advertising, PRIOR RESULTS DO NOT GUARANTEE A SIMILAR OUTCOME. Reproduction: Reproduction of reasonable portions of the Content is permitted provided that (i) such reproductions are made available free of charge and for non-commercial purposes, (ii) such reproductions are properly attributed to Baker McKenzie, (iii) the portion of the Content being reproduced is not altered or made available in a manner that modifies the Content or presents the Content being reproduced in a false light and (iv) notice is made to the disclaimers included on the Content. The permission to re-copy does not allow for incorporation of any substantial portion of the Content in any work or publication, whether in hard copy, electronic or any other form or for commercial purposes.